Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Opinion · CompePharma View

Adjusted EBITDA is the headline number. This earnings season shows why the bridge matters more

Harrow, Liquidia and CorMedix each reported strong operating metrics beside very different GAAP and guidance pictures. Leaders should judge the bridge between those numbers, not the number on top.

16 Nov 2026 · CompePharma editorial

The number everyone quotes, and what sits beneath it

Adjusted EBITDA has become the pharma industry's preferred shorthand for operating health. This quarter's results show how much that shorthand leaves out when it is read alone.

Liquidia is the starkest case. YUTREPIA net product sales reached $222.7 million, up 31% from the second quarter. Adjusted EBITDA rose to $140.5 million, the fifth consecutive quarterly increase. The company also reported a net loss of $236.3 million, driven by a $389.7 million litigation settlement charge. Its $396.1 million cash balance is described as 'prior to settlement payments'. All three numbers are accurate, and none tells the story alone. The bridge from one to the next is the story.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More Opinion · CompePharma ViewAll →
Opinion · CompePharma View

A guidance raise is only as good as who controls the trigger

Q3 guidance moves look alike on a headline but differ in what they say about control. The companies that own their drivers have earned more trust than those waiting on a partner's calendar.

15 Nov 2026 · CompePharma editorial